Preprint
Article

This version is not peer-reviewed.

Elevated Proportions of Activated NK Cells at Diagnosis Predict a Favourable Prognosis in Glioblastoma Patients

Submitted:

10 December 2020

Posted:

11 December 2020

Read the latest preprint version here

Abstract
Despite rapid progress in the treatment of many cancers, glioblastoma remains a devastating disease with dismal prognosis. Recombinant heat shock protein 70 (Hsp70) and IL-2 stimulate the cytolytic activity of NK cells against a large variety of highly aggressive human tumor cells presenting Hsp70 on their cell surface. Therefore, the intra- and extracellular Hsp70 expression was determined in gliomas together with activatory NK cell receptors which are known to interact with membrane-bound Hsp70 (mHsp70). All gliomas are mHsp70-positive and high grade gliomas overexpress Hsp70 in the nucleus and cytosol. Significantly increased extracellular Hsp70 levels are detected predominantly in glioblastomas with large necrotic areas. Overall survival (OS) is improved in patients with low Hsp70 serum levels indicating that high Hsp70 expression levels are associated with unfavorable prognosis. Progression-free survival (PFS) in glioblastoma patients correlates with elevated proportions of activated NK cells (CD56+/CD94+, CD3-/CD69+) at diagnosis. The stimulation of these NK cells in vivo might be related to the presence pro-inflammatory cytokines and the Danger Associated Pattern Molecule (DAMP) Hsp70 in the circulation. Of caution, glucocorticoid therapy reduces the prevalence of activated NK cells. In summary, elevated frequencies of activated NK cells at diagnosis predict a more favorable prognosis in glioblastoma patients.
Keywords: 
;  ;  ;  ;  
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

Subscribe

Disclaimer

Terms of Use

Privacy Policy

Privacy Settings

© 2026 MDPI (Basel, Switzerland) unless otherwise stated